PRAZOSIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Prazosin Hydrochloride patents expire, and what generic alternatives are available?
Prazosin Hydrochloride is a drug marketed by Alembic, Am Therap, Ani Pharms, Appco, Aurobindo Pharma Ltd, Dava Pharms Inc, Granules, Lannett Co Inc, Mankind Pharma, MSN, Mylan, Novitium Pharma, Purepac Pharm, Teva Pharms, and Watson Labs. and is included in twenty-three NDAs.
The generic ingredient in PRAZOSIN HYDROCHLORIDE is prazosin hydrochloride. There is one drug master file entry for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Prazosin Hydrochloride
A generic version of PRAZOSIN HYDROCHLORIDE was approved as prazosin hydrochloride by TEVA PHARMS on September 12th, 1988.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PRAZOSIN HYDROCHLORIDE?
- What are the global sales for PRAZOSIN HYDROCHLORIDE?
- What is Average Wholesale Price for PRAZOSIN HYDROCHLORIDE?
Summary for PRAZOSIN HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 15 |
| NDAs: | 23 |
| Finished Product Suppliers / Packagers: | 33 |
| Raw Ingredient (Bulk) Api Vendors: | 117 |
| Clinical Trials: | 71 |
| Patent Applications: | 2,737 |
| What excipients (inactive ingredients) are in PRAZOSIN HYDROCHLORIDE? | PRAZOSIN HYDROCHLORIDE excipients list |
| DailyMed Link: | PRAZOSIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for PRAZOSIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer | PHASE1 |
| University of Wisconsin, Madison | PHASE2 |
| National Institute of Neurological Disorders and Stroke (NINDS) | PHASE2 |
Pharmacology for PRAZOSIN HYDROCHLORIDE
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
